Update on the emerging role of telavancin in hospital-acquired infections

• Main Authors: Nnedu ON, Pankey GA
• Format: Article
• Language: English
• Published: Dove Medical Press 2015-04-01
• Series: Therapeutics and Clinical Risk Management
• Online Access: http://www.dovepress.com/update-on-the-emerging-role-of-telavancin-in-hospital-acquired-infecti-peer-reviewed-article-TCRM

Obinna N Nnedu,1 George A Pankey2 1Infectious Disease Department, Ochsner Clinic Foundation, New Orleans, LA, USA; 2Infectious Disease Research, Ochsner Clinic Foundation, New Orleans, LA, USA Abstract: Telavancin is a lipoglycopeptide that has activity against gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research. Keywords: telavancin, vancomycin, linezolid, Staphylococcus aureus